Agrow is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. Please do not redistribute without permission.

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

US patent for another MBI bioherbicide

The US biopesticide company, Marrone Bio Innovations (MBI - Davis, California), has been granted a US patent for another bioherbicide active ingredient, thaxtomin. The patent (8,476,195) covers thaxtomin A and similar compounds for use as pre- and post-emergence herbicides against most common weeds in cereals and turf in agricultural and residential settings. Thaxtomins are phytotoxins produced by Streptomyces spp bacteria. MBI received US approval for an S acidiscabies-based bioherbicide, MBI-005, last year (Agrow No 640, p 20). Last month, the company received a US patent for sarmentine, the ai in its bioherbicide, MBI-011 (Agrow No 668, p 30). "We are very excited about the broad activity of thaxtomin, either alone or in a synergistic tank mix. With two herbicide active ingredients now patented we are optimistic that MBI will be able to fill the gaps in the underserved bioherbicide product category," says the company's vice-president of research and development, Dr Phyllis Himmel.

Advertisement

Topics

What to read next

Advertisement
UsernamePublicRestriction

Register

AG000239

Ask The Analyst

Please fill in the form below to send over your enquiry or check the Ask The Analyst Page to find out more about the service

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel